Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Formaldehyde levels in building environments are affected by a number of factors. These include the potency of formaldehyde-emitting products present, the ratio of the surface area of emitting materials to volume of space, environmental factors, product age, interactions with other materials, and ventilation conditions. Formaldehyde emits from a variety of construction materials, furnishings, and consumer products. The three products that emit the highest concentrations are medium-density fiberboard, hardwood plywood, and particle board. Environmental factors such as temperature and relative humidity can elevate levels because formaldehyde has a high vapor pressure. Formaldehyde levels from building materials are the highest when a building first opens because materials would have less time to off-gas. Formaldehyde levels decrease over time as the sources suppress. In operating rooms, formaldehyde is produced as a byproduct of a process known as electrosurgery and is present in surgical smoke, exposing surgeons and healthcare workers to potentially unsafe concentrations. Formaldehyde levels in air can be sampled and tested in several ways, including impinger, treated sorbent, and passive monitors. The National Institute for Occupational Safety and Health (NIOSH) has measurement methods numbered 2016, 2541, 3500, and 3800.
Defatted soy flour is obtained from solvent extracted flakes and contains less than 1% oil. "Natural or full-fat soy flour is made from unextracted, dehulled beans and contains about 18% to 20% oil." Its high oil content requires the use of a specialized Alpine Fine Impact Mill to grind rather than the usual hammer mill. Full-fat soy flour has a lower protein concentration than defatted flour. Extruded full-fat soy flour, ground in an Alpine mill, can replace/extend eggs in baking and cooking. Full-fat soy flour is a component of Cornell bread. Low-fat soy flour is made by adding some oil back into defatted soy flour. Fat levels range from 4.5% to 9%. High-fat soy flour can also be produced by adding back soybean oil to defatted flour, usually at 15%. Soy lecithin can be added (up to 15%) to soy flour to make lecithinated soy flour. It increases dispersibility and gives it emulsifying properties. Soy flour has 50% protein and 5% fiber. It has higher levels of protein, thiamine, riboflavin, phosphorus, calcium, and iron than wheat flour. It does not contain gluten. As a result, yeast-raised breads made with soy flour are dense in texture. Among many uses, soy flour thickens sauces, prevents staling in baked food, and reduces oil absorption during frying. Baking food with soy flour gives it tenderness, moistness, a rich color, and a fine texture. Soy grits are similar to soy flour, except the soybeans have been toasted and cracked into coarse pieces. Kinako is a soy flour used in Japanese cuisine. Section reference: Circle & Smith (1972, p. 442)
beaker A cylindrical vessel or container with a flat bottom, most commonly a type of glassware, widely used in laboratories for a variety of purposes, such as preparing, holding, containing, collecting, or volumetrically measuring chemicals, samples, or solutions, or as a chamber in which a chemical reaction occurs. Beakers are distinguished from flasks by having straight rather than sloping sides; most beakers also have a small spout in the rim to aid pouring.
For services to Child Road Safety. Kenneth Fitzpatrick. Lifeboat Operations Manager, Porthdinllaen Lifeboat Station, Royal National Lifeboat Institution. For services to Maritime Safety. Barry Flack. For services to the Jewish Community in the London Borough of Barnet. Margaret Elizabeth Flanagan. Member, Inner Wheel Club of Ballymena. For voluntary services to the community in Ballymena, County Antrim. John Campbell Forrester. President and Poppy Appeal Organiser, Driffield Branch, Royal British Legion. For voluntary service to Veterans in East Yorkshire. Claire Forsythe. Duke of Edinburgh's Award Officer, Probation Board for Northern Ireland. For services to the Rehabilitation of Offenders. Susan Joan Foster. For voluntary service in Hampshire. Richard Charles Fowler. Library Lead, Harbury Community Library, Warwickshire. For services to Libraries. Dr Jennifer Ann Frow. Volunteer, Bewdley Tennis Club. For services to Lawn Tennis in Worcestershire. Robert Francis Fyfe. Chair and Director, Runway Theatre Company. For services to the Arts and to the community in Glasgow. Melanie Jane Gardner. Fine and Decorative Arts Curator, Tullie House Museum, Carlisle. For services to Arts and Culture in Cumbria. Joseph William Garvey. For services to the community in County Armagh. Peter William Garwood. For services to the community in Barrow-in-Furness, Cumbria. Christine Frances Gatfield. Founder, Dove Cottage Day Hospice. For services to the Terminally Ill. Patricia Mary Gaywood. Membership Secretary, The Forty Club. For voluntary service to Cricket. Andrew Gell.
== PAD subtypes == PADs are found in chordates but not in lower animals. In mammals five PAD isotypes – PAD1, PAD2, PAD3, PAD4 and PAD6 – have been found. PAD5 was thought to be a unique isotype in humans, however it was shown to be homologous to PAD4. These isotypes differ in terms of their tissue and cellular distributions. PAD1 expression has been detected in epidermis and the uterus, and it acts in citrullination of keratin and filaggrin, key components of keratinocytes. PAD2 is expressed at a high level in the central nervous system, including the eye and brain, as well as skeletal muscle and the spleen. PAD transcripts have been found in the C57BL6/J mouse eyes as early as embryonic day 14.5. PAD2 has also been shown to interact with vimentin in skeletal muscle and macrophages, causing the filaments to disassemble, suggesting a role in apoptosis. One of PAD2's target substrates is myelin basic protein. In the normal retina, deimination is found in nearly all the retinal layers, including the photoreceptors. Deimination has been also reported in neuronal cells, such as astrocytes, microglia and oligodendrocytes, Schwann cells and neurons. Methylation and phosphorylation of myelin basic protein are active during the process of myelinogenesis. In early development of the central nervous system of the embryo, deimination of myelin basic protein plays a major role in myelin assembly. In adults, deimination myelin basic protein occurs in demyelinating diseases such as multiple sclerosis. Myelin basic protein may affect different cell types in each case.
Sources: en.wikipedia.org
But when he finally presented his results he reported an excess heat of only one degree Celsius, a result that could be explained by chemical differences between heavy and light water in the presence of lithium. He had not tried to measure any radiation and his research was derided by scientists who saw it later. For the next six weeks, competing claims, counterclaims, and suggested explanations kept what was referred to as "cold fusion" or "fusion confusion" in the news. In April 1989, Fleischmann and Pons published a "preliminary note" in the Journal of Electroanalytical Chemistry. This paper notably showed a gamma peak without its corresponding Compton edge, which indicated they had made a mistake in claiming evidence of fusion byproducts. Fleischmann and Pons replied to this critique, but the only thing left clear was that no gamma ray had been registered and that Fleischmann refused to recognize any mistakes in the data. A much longer paper published a year later went into details of calorimetry but did not include any nuclear measurements. Nevertheless, Fleischmann and Pons and a number of other researchers who found positive results remained convinced of their findings. The University of Utah asked Congress to provide $25 million to pursue the research, and Pons was scheduled to meet with representatives of President Bush in early May. On 30 April 1989, cold fusion was declared dead by The New York Times. The Times called it a circus the same day, and the Boston Herald attacked cold fusion the following day.
=== Norway === The Norwegian Armed Forces use a 24-hour ration pack (Norwegian: feltrasjon) designed by Drytech, consisting of 2 freeze-dried main meals, a packet of compressed breakfast cereal, packets of instant soup, and supplements. These are packed in 3 green polylaminate bags labelled "Breakfast", "Lunch", or "Dinner", overwrapped in clear plastic and issued as one day's ration. Depending on the soldiers activity, the rations are delivered in two different sizes of either 3800 kcal or 5000 kcal. Included are a substantial assortment of beverages (cocoa mix, instant coffee, energy drink powder, and herbal teas), plus thin sliced rye bread and chocolate, chewing gum, a vitamin tablet, and litter bags. There are 7 completely different menus, and ongoing development to meet different nations requirements. The main meals are for example Chili con carne, different pasta dishes, Beef Stew, Beef and Potato Casserole, Lamb Mulligatawny, Cod and Potato Casserole, Pasta Bolognese, Wolf-fish with Prawns and Dill, Sweet and Sour Chicken, Rice in Basil Sauce etc. Small tins of fish are often provided separately.
Its cavalry included 400 men from the Cape Mounted Riflemen, 600 men from the Cape Mounted Yeomanry (CMY), 200 riders from Kimberley Horse, as well as small units of scouts and African levies. Its infantry consisted of the Prince Alfred Volunteer Guards, Duke of Edinburgh's Volunteer Guards and First City Volunteer Rifles, each numbering 100 to 200 soldiers. The force also included three RML 7-pounder mountain guns and two 5.5-inch mortars. A total of 3,000 white and 1,000 African troops were involved in the campaign. The Basuto vastly outnumbered their adversaries, Lerotholi commanded 23,000 cavalry, of which 9,000 were concentrated in the Mafeteng District where most of the fighting took place. A part of the Basuto army was tasked with guarding Letsie's ancestral village of Morija. Masopha blockaded the garrison of 200 CMR soldiers at Maseru. He burned Maseru's main buildings in his first assault on the town, but further attacks proved less successful. In the north, Joel Molapo's attack on Hlotse was likewise repulsed and he initiated a siege. The magistracies at Mohale's Hoek and Quthing were abandoned by the Cape troops. The rebellion continued to spread across Basutoland, with clashes taking place across seven different fronts. The heavy casualties suffered by the Basuto during their frontal assaults caused them to increasingly adopt the tactics of the Boer Commando; employing ambushes and defending fortified positions. Their high mobility allowed them to engage their opponents only when they believed that conditions favored them and to quickly withdraw after firing.
shuttle vector A DNA molecule (e.g. a plasmid), natural or engineered, that is capable of replicating in two or more different host organisms and which can therefore be used to convey genetic material between them.
== Purification == Synthesized carbon nanotubes typically contain impurities and most importantly different chiralities of carbon nanotubes. Therefore, multiple methods have been developed to purify them including polymer-assisted, density gradient ultracentrifugation (DGU), chromatography and aqueous two-phase extraction (ATPE). These methods have been reviewed in multiple articles. Certain polymers selectively disperse or wrap CNTs of a particular chirality, metallic character or diameter. For example, poly(phenylenevinylenes) disperse CNTs of specific diameters (0.75–0.84 nm) and polyfluorenes are highly selective for semiconducting CNTs. Separation involves mainly two steps: sonicate the mixture (CNTs and polymers in solvent), then centrifuge. The supernatant will contain the desired CNTs. Density gradient ultracentrifugation is based on the density difference of CNTs, so that different components are layered in centrifuge tubes under centrifugal force. Chromatography-based methods include size exclusion (SEC), ion-exchange (IEX) and gel chromatography. For SEC, CNTs are separated due to the difference in size using a stationary phase with different pore size. As for IEX, the separation is achieved based on their differential adsorption and desorption onto chemically functionalized resins packed in an IEX column, so understanding the interaction between CNTs mixtures and resins is important. The first IEX was reported to separate DNA-SWCNTs. Gel chromatography is based on the partition of CNTs between stationary and mobile phase.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.